

Barbara J. Osborne has joined LEO as the President and CEO of LEO US, effective today. Barbara brings along extensive experience from successfully leading and growing US organisations within the medical device industry. One of her many achievements was to successfully grow sales – moving from a #5 position to being the market leader.

LEO US is a key asset to LEO and plays an important role in our global journey towards becoming the preferred dermatology care partner. Most importantly, however, is that we now have a solid platform in the largest pharmaceutical market in the world from which we can grow our current as well as our future patient solution portfolio.

*“With Barbara on board and with the recently announced changes endorsed by Barbara, I am confident that the strong LEO US team will be able to grow our US business to the benefit of first and foremost our patients.” says Lars Olsen, Executive Vice President, Global Sales & Marketing.*

From now and until mid-December, Jørgen Damsbo Andersen, who has been acting as interim President and CEO of LEO US, will stay in the US to ensure a thorough handover to Barbara and to support the recently announced restructuring of the US organization.

As of 1 January 2015, Jørgen Damsbo Andersen will resume his duties as Regional Vice President for Region EU5+.